Most Read Articles
23 Nov 2018
Initial acute respiratory illness (ARI) admissions related to human adenovirus (HAdV), human metapneumovirus (hMPV) and human rhinovirus (HRV) occurring during early infancy increase the risk of subsequent ARI-related readmission, a recent study has shown.
Roshini Claire Anthony, 19 Dec 2019

First-line treatment with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) dacomitinib demonstrated persistent survival benefit in patients with EGFR-positive advanced non-small cell lung cancer (NSCLC), according to updated results from the phase III ARCHER 1050* trial.

Pearl Toh, 03 Dec 2018
Sequential treatment with afatinib followed by osimertinib enables prolonged chemotherapy-free treatment while sustaining clinical benefit in patients with EGFR-mutation positive (EGFR+) non-small–cell lung cancer (NSCLC) who acquire T790M mutation, according to the real-world retrospective GioTag study presented at ESMO Asia 2018.

PRoFeSs score reliably predicts poor outcomes in severe community-acquired pneumonia

11 Aug 2019

The PRoFeSs score―which includes the Charlson score, as well as levels of day 3 lactate, day 1 and day 3 procalcitonin, day 3 D-dimer, and day 1 brain-type natriuretic peptide (BNP)―can identify severe community-acquired pneumonia (SCAP) patients at high risk of poor outcomes 5 days after ICU admission, a recent study has found.

Researchers conducted a single-centre, prospective cohort study including 107 ICU patients (mean age, 62.0±15.7 years; 60.7 percent male) diagnosed with SCAP. The study’s primary outcome included death and the lack of ≥2-point improvements in scores in the Sequential Organ Failure Assessment within 5 days of treatment.

Six variables emerged as significantly predictive of the primary outcome. For instance, Charlson score (adjusted odds ratio [OR], 1.330, 95 percent CI, 1.059–1.669; p=0.021) and day 3 concentrations of D-dimer (adjusted OR, 2.185, 1.352–3.530; p=0.001) were strongly and positively correlated with the likelihood of the primary outcome.

The same was true for day 3 concentrations of procalcitonin (adjusted OR, 1.635, 0.993–4.692; p=0.016) and lactate (adjusted OR, 1.954, 1.093–3.498; p=0.03).

In comparison, day 1 levels of BNP (adjusted OR, 0.950, 0.901–1.001; p=0.047) and procalcitonin (adjusted OR, 0.572, 0.355–0.922; p=0.003) were significantly but inversely correlated with the primary outcome.

Consolidating all factors into one predictive model produced the PRoFeSs score, which had an area under the receiver operating characteristic curve of 0.81 (0.72–0.89). At a cutoff of 3 points, sensitivity and specificity are both maximized, yielding values of 79 percent and 71 percent, respectively.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
23 Nov 2018
Initial acute respiratory illness (ARI) admissions related to human adenovirus (HAdV), human metapneumovirus (hMPV) and human rhinovirus (HRV) occurring during early infancy increase the risk of subsequent ARI-related readmission, a recent study has shown.
Roshini Claire Anthony, 19 Dec 2019

First-line treatment with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) dacomitinib demonstrated persistent survival benefit in patients with EGFR-positive advanced non-small cell lung cancer (NSCLC), according to updated results from the phase III ARCHER 1050* trial.

Pearl Toh, 03 Dec 2018
Sequential treatment with afatinib followed by osimertinib enables prolonged chemotherapy-free treatment while sustaining clinical benefit in patients with EGFR-mutation positive (EGFR+) non-small–cell lung cancer (NSCLC) who acquire T790M mutation, according to the real-world retrospective GioTag study presented at ESMO Asia 2018.